Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaOsteonecrosis in children with acute lymphoblastic leukemiaExtranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseEffect of premedications in a murine model of asparaginase hypersensitivityAntileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.Inherited genetic variation in childhood acute lymphoblastic leukemia.Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse ModelGenetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemiaPediatric acute lymphoblastic leukemia: where are we going and how do we get there?Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutAsparaginase-associated toxicity in children with acute lymphoblastic leukemia.Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).High-throughput asparaginase activity assay in serum of children with leukemiaA 50-year journey to cure childhood acute lymphoblastic leukemiaL-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.Asparaginase-associated pancreatitis in children.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.Asparaginase pharmacology: challenges still to be faced.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional studySevere pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Reactions related to asparaginase infusion in a 10-year retrospective cohort.A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy.Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
P2860
Q26738640-8D3C4835-E6DC-45CF-A55B-775AEC2B1067Q26784116-B8B73B22-A2DF-43EE-B901-134C87E89FDEQ26825970-EA5B9FCF-975E-4CCE-B9AE-A959472D978CQ27026476-E2016E01-AC97-40C9-98FB-D08655E7C9CAQ27026952-6E2BA122-2215-4946-92C4-96360BA53CA8Q28066799-4B1A00B8-7001-4BE5-B2B1-4207EEC22DD7Q30244110-ED34FA62-D19F-4C77-BE39-1671933D8959Q30371340-CD06757F-786F-424D-B41E-0BFBAB60127FQ33557148-45A00DB4-C583-48F6-8979-CD3B5A95991BQ34064049-58B163F7-5F4B-4652-A480-EB3F3D4CE333Q35156439-AB11143C-C0B6-4701-AD91-D9CBB374625CQ35740019-E303B19F-2E93-49D5-950B-79DAC4DF0769Q35784497-2CADF80F-E692-46D3-A3D7-313534B82703Q35820373-999739AA-A2CC-4C53-AA91-F45428CD8877Q35954058-98B954C2-B4EF-409D-AA12-955BA8362F00Q36143232-68270C09-841A-471C-A506-7F782CCA1ED3Q36163029-7FFE2CE3-182C-42A1-B42B-671D6EAD552EQ36678136-052BC259-7C8D-42C3-BB5D-400E85C38733Q36762608-CDEB0132-E225-41BC-8123-0F10B19A8926Q36895136-998AFF81-8F70-41DC-A70F-CC81EED217E0Q37063860-E6F005CF-4313-4E2D-BA92-9D039FAE0EE5Q37166753-B41FBC29-4135-4809-87E2-741355038B61Q37379199-2DA6DA2F-BDBF-42E1-9FE9-8481ECB99694Q38036389-3C5A894F-4824-44BD-A878-E6F22F2696BDQ38079075-4B303BB8-FC58-4C5D-8D0D-2B2F3C0B8642Q38132699-753E486A-16B3-417B-8A07-58678771E471Q38821455-23F39EDF-D677-4A1B-90D2-798ECA138842Q38880102-528F56EF-8401-4AF8-85D4-E95BAFF5B05DQ38933372-5DE811ED-2901-428D-B25D-3E4DA349DBBAQ38941947-E7B5AA01-FF68-48A4-B8DC-B2CE36A68446Q39135887-AC30F590-5F5C-42A4-BE54-AC361EDAE349Q39194553-7BC604C5-6938-4116-9757-EC50FD207480Q40243523-498D9D5E-BD7E-467E-9D4D-6C28AAF26171Q41491082-5E50CF9D-9E4E-4ABC-AC7C-A8DBBA91770BQ45072276-EE680687-7F98-4A42-B949-7BAEB33BAC9EQ47133515-74A6ABD6-1187-4B39-A457-0CE8BFAB40BFQ47608786-AFA7CDEB-33A3-48CA-8CE4-1C53C2CDA0C1Q48203946-E7F0FCE4-523A-4F37-9321-245F4D58F45AQ51071633-3E4D15A0-C659-4A77-92E3-1311AEF5442AQ51664868-8B87EB27-F90E-483B-981D-AE9AF9A92D8C
P2860
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@ast
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@en
type
label
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@ast
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@en
prefLabel
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@ast
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1433
P1476
Clinical utility and implicati ...... acute lymphoblastic leukemia.
@en
P2093
C A Fernandez
J C Panetta
J D Kawedia
J T Sandlund
M V Relling
P2860
P2888
P304
P356
10.1038/LEU.2012.102
P577
2012-04-09T00:00:00Z